This content is for healthcare professionals only.

This activity is funded by an independent medical education grant from Agios Pharmaceuticals Inc., Pfizer and Vertex Pharmaceuticals.

This activity is jointly provided by USF Health and touchIME.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues

    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Biree Andemariam

    University of Connecticut Health, Farmington, CT, USA

    Prof. Andemariam is professor of medicine and the American Red Cross Endowed Chair at the University of Connecticut School of Medicine, CT, USA. She is a physician scientist in the Division of Hematology/Oncology, founding director of the New England Sickle Cell Institute and director of the Connecticut Bleeding Disorders Center. read more

    Prof. Andemariam has been lead principal investigator of several global sickle cell disease clinical trials and registry studies. Her research interests include defining the intracellular signalling pathways involved in sickle vaso-occlusion and developing/implementing care pathways that lead to improved patient outcomes and health resource utilization.

    Disclosures

    Prof. Biree Andemariam discloses: Grants/research support from Forma Therapeutics, Global Blood Therapeutics, Hemanext, Novartis, Novo Nordisk and Pfizer. Consulting fees from Accordant, Emmaus (Relationship Terminated) and GlaxoSmithKline. Advisory board or panel fees from Afimmune, Agios Pharmaceuticals, Bluebird Bio, Forma Therapeutics, Global Blood Therapeutics, Hemanext, Novartis, Novo Nordisk, Pfizer, Sanofi Genzyme and Vertex Pharmaceuticals.
    Prof. Modupe Idowu

    University of Texas Health Science Center, McGovern Medical School, Houston, TX, USA

    Prof. Idowu is professor of medicine in the Division of Hematology at the University of Texas (UT) Health Science Center, McGovern Medical School in Houston, TX, USA. She is the director of the Division of Hematology, associate programme director of the Hematology/Oncology Fellowship and medical director of UT Physicians Comprehensive Sickle Cell Center. read more

    Prof. Idowu is an active member of the American Society of Hematology, American Federation for Medical Research and the National Medical Association. Her clinical interests include sickle cell anaemia, other anaemias, thrombocytopenia, leukopenia and bone marrow disorders. In addition to serving as principal investigator for more than 12 clinical trials, Prof. Idowu is also a reviewer for numerous scientific journals.

    Disclosures

    Prof. Modupe Idowu discloses: Grants/research support from Agios Pharmaceuticals, Alexion, Forma, Global Blood Therapeutics, Novartis, Novo Nordisk and Pfizer. Consulting fees from Global Blood Therapeutics, Novartis and Novo Nordisk. Advisory board or panel fees from Global Blood Therapeutics, Novartis and Novo Nordisk. Speaker’s bureau fees from Global Blood Therapeutics.
    Prof. Mark C Walters

    University of California, San Francisco, Oakland, CA, USA

    Prof. Walters is the Jordan Family Director of the Blood and Marrow Transplantation Program at University of California San Francisco (UCSF) Benioff Children’s Hospital, Oakland, CA, USA. He is professor and chief of the Hematology Division in the Department of Pediatrics at UCSF School of Medicine, and is programme director of the California Institute of Regenerative Medicine Alpha Stem Cell Clinic at UCSF. read more

    Prof. Walters is active in cooperative clinical transplantation trials and has led several National Institutes of Health-supported investigations of haematopoietic cell transplantation for sickle cell anaemia and thalassaemia. His research interests include haematopoietic cell transplantation for haemoglobin disorders, novel cellular therapies for non-malignant haematological disorders, and the use of genomic editing and gene addition therapies as a strategy to extend curative therapy in patients with a clinically significant haemoglobinopathy.

    Disclosures

    Prof. Mark C Walters discloses: Consulting fees from AllCells and BioChip Labs. Advisory board or panel fees from Ensoma and Vertex Pharmaceuticals.
    Back to Faculty
    touchHAEMATOLOGY touchHAEMATOLOGY
    Start activity
     
    Videos Take ACPE Test
    Genetic Blood Disorders CE/CME accredited

    touchPANEL DISCUSSION
    A visually engaging discussion designed to emulate a ‘live’ panel experience and provide clinicians with practical expert insights to address their clinical challenges. Useful tips below will show how to navigate the activity. Close

    Contemporary insights on the management of sickle cell disease: Focus on complications and recent advances in therapy

    Useful tips
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Summarize the various manifestations and multiple complications of SCD
    • Appraise the practical considerations for the multidisciplinary management of SCD complications
    • Interpret the clinical data for established and recently approved therapies for SCD and apply them to clinical practice
    Overview

    In this activity, three experts provide their perspectives on the clinical manifestations and complications of sickle cell disease (SCD), the multidisciplinary management of these complications, and established and recently approved therapies. The discussion is guided by pre-canvassed questions provided by healthcare professionals involved in the management of patients with SCD.

    This activity is jointly provided by USF Health and touchIME. read more

    Target Audience

    Cardiologists (including paediatric cardiologists), emergency medicine physicians, haematologists (including paediatric haematologists), hospital pharmacists, neurologists, nurse practitioners, paediatricians and primary care physicians involved in the management of sickle cell disease.

    Disclosures

    USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

    Faculty

    Prof. Biree Andemariam discloses: Grants/research support from Forma Therapeutics, Global Blood Therapeutics, Hemanext, Novartis, Novo Nordisk and Pfizer. Consulting fees from Accordant, Emmaus (Relationship Terminated) and GlaxoSmithKline. Advisory board or panel fees from Afimmune, Agios Pharmaceuticals, Bluebird Bio, Forma Therapeutics, Global Blood Therapeutics, Hemanext, Novartis, Novo Nordisk, Pfizer, Sanofi Genzyme and Vertex Pharmaceuticals.

    Prof. Modupe Idowu discloses: Grants/research support from Agios Pharmaceuticals, Alexion, Forma, Global Blood Therapeutics, Novartis, Novo Nordisk and Pfizer. Consulting fees from Global Blood Therapeutics, Novartis and Novo Nordisk. Advisory board or panel fees from Global Blood Therapeutics, Novartis and Novo Nordisk. Speaker’s bureau fees from Global Blood Therapeutics.

    Prof. Mark C Walters discloses: Consulting fees from AllCells and BioChip Labs. Advisory board or panel fees from Ensoma and Vertex Pharmaceuticals.

    Nurse Planner and Content Reviewer

    Amy Patterson MSN, APRN, AOCNS®, BMTCN® discloses the following:
    Speakers Bureau: Gilead/Kite (Relationship Terminated).

    Pharmacist Reviewer

    Rebecca Gonzalez, PharmD BCOP has no relevant financial relationships to disclose.

    Touch Medical Contributors

    Sola Neunie has no financial interests/relationships or affiliations in relation to this activity.

    USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

    Requirements for Successful Completion

    In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

    If you have questions regarding credit please contact cpdsupport@usf.edu.

    Accreditations

    Physicians

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

    USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    Advanced Practice Providers

    Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

    The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

    Pharmacists

    USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 0.75 contact hours (0.75 CEUs). Universal Activity Number (UAN) is as follows: 0230-9999-23-015-H01-P.

    Nurses

    USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

    A maximum of 0.75 contact hour may be earned by learners who successfully complete this  continuing professional development activity. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE activity.

    Date of original release: 16 August 2023. Date credits expire: 16 August 2024.

    If you have any questions regarding credit please contact cpdsupport@usf.edu.

    This activity is CE/CME accredited

    To obtain contact hours from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    touchPANEL DISCUSSION

    Contemporary insights on the management of sickle cell disease: Focus on complications and recent advances in therapy

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    touchPANEL DISCUSSION

    Navigating pyruvate kinase deficiency today: How can the disease burden and unmet treatment needs be addressed?

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    Topics covered in this activity

    Genetic Blood Disorders
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 10 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This Activity Is Funded By:

    An independent medical education grant from Alexion Pharmaceuticals.
    This activity is jointly provided by USF Health and touchIME in collaboration with our Education Partner the Haematology Nurses & Healthcare Professionals Group (HNHCP).

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Date of original release: 16 August 2023. Date credits expire: 16 August 2024.

    Claim Credit
    touchPANEL DISCUSSION
    Contemporary insights on the management of sickle cell disease: Focus on complications and recent advances in therapy
    0.75 CE/CME credit
    Question 1/4
    Which of the following factors could exacerbate acute complications in patients with sickle cell disease?

    Increased pain sensitivity to cold and heat stimuli and a lower threshold to cold/heat detection is well established in patients with sickle cell disease.1 Cold weather is a common precipitant of acute pain2,3 and patients are advised to keep warm in cold weather.2

    References

    1. Brandow AM, et al. Am J Hematol. 2013;88:37–43.
    2. Rees DC, et al. Blood Rev. 2022;56:100983.
    3. Druye AA, et al. Chronic Illn. 2023 doi:10.1177/17423953231172797.
    Question 2/4
    You have confirmed a diagnosis of homozygous sickle cell disease (HbSS) in a newborn baby and her mother asks what to expect in terms of complications associated with the disease. You advise that patients with sickle cell disease are at risk of which complication?

    Stroke is a recognized major complication of sickle cell disease.1 In a retrospective review of cases between 2016 and 2019, 24/161 (14%) of patients aged ≥18 years with HbSS experienced ischaemic stroke, either symptomatic or silent.1 The most common cause of ischaemic stroke was large vessel occlusion (2.9%).1 In addition, a retrospective analysis of data from the STOP and STOP II clinical trials of patients with homozygous sickle cell disease (HbSS) showed that the risk of haemorrhagic stroke increases with age.2 Screening for stroke risk using transcranial Doppler ultrasound and appropriate management for those at high risk is effective for primary stroke prevention.3

    References

    1. Maduakor C, et al. Front Neurol. 2021;12:744118.
    2. Fox CK, et al. Stroke. 2022;53:e463–6.
    3. Kirkham FJ, Lagunju IA. J Clin Med. 2021;10:4232.
    Question 3/4
    A 20-year-old patient with confirmed sickle cell disease presents to you in the emergency department with a 2-day history of arm and leg pain that has worsened despite analgesia. He also reports severe pleuritic chest pain and dyspnoea that began today. Which of the following complications would you investigate at this stage?

    ACS should be suspected in patients with sickle cell disease presenting with acute respiratory symptoms during a vaso-occlusive crisis. In adults, ACS is characterized by chest pain, dyspnoea, limb pain or a vaso-occlusive crisis in another part of the body; 78% of presentations occur secondary to acute vaso-occlusive pain events. Early diagnosis and management of ACS can reduce mortality and length of hospital stay. Investigation for ACS should include chest imaging for identification of new pulmonary infiltrates and to exclude other respiratory pathology.

    Abbreviation

    ACS, acute chest syndrome.

    Reference

    Friend A, et al. 2023. Available at: https://bit.ly/3QcXozu (accessed 25 July 2023).

    Question 4/4
    The phase III HOPE trial investigated the safety and efficacy of voxelotor 1500 mg once daily in patients aged 12–65 years with sickle cell disease. Which of the following was reported with voxelotor treatment, compared with placebo?

    In the HOPE trial, a haemoglobin response (increase from baseline of >1.0 g/dL at week 24) was seen in significantly more patients treated with voxelotor 1500 mg than placebo (51 vs 7%; p<0.001). The least squares mean change in haemoglobin level from baseline to week 24 was significantly greater in the voxelotor 1500 mg group than the placebo group (+1.1 vs −0.1 g/dL; p<0.001).

    Reference

    Vichinsky E, et al. N Engl J Med. 2019;381:509–19.

    Back to Activity

    You may also be interested in...

    touchPANEL DISCUSSION

    Contemporary insights on the management of sickle cell disease: Focus on complications and recent advances in therapy

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    touchPANEL DISCUSSION

    Navigating pyruvate kinase deficiency today: How can the disease burden and unmet treatment needs be addressed?

    This activity is CE/CME accredited
    LAUNCH ACTIVITY
    This Activity Is Funded By:

    An independent medical education grant from Alexion Pharmaceuticals.
    This activity is jointly provided by USF Health and touchIME in collaboration with our Education Partner the Haematology Nurses & Healthcare Professionals Group (HNHCP).

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Date of original release: 16 August 2023. Date credits expire: 16 August 2024.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72